Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Guangdong Pharmaceutical University
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03706326CT.gov CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| pd-1 knockout engineered t cells (this asset) | The First Affiliated Hospital of Guangdong Pharmaceutical University | P1/2 | CCC · 48 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| Fluorouracilum | Merck Sharp & Dohme LLC | P4 | BB |
| Pembrolizumab | Essen Biotech | P3 | B |
| Epirubicin | Sutro Biopharma, Inc. | P3 | B |
| Docetaxel | Laekna Limited | P2 | B |
| Cetirizine | Ciusss de L'Est de l'Île de Montréal | P3 | B |
| Cyclophosphamide | Sutro Biopharma, Inc. | P3 | B |
| Carboplatin | Neonc Technologies, Inc. | P2 | B |
+42 more in the Esophageal Cancer cohort
Other indications for pd-1 knockout engineered t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1/2 | CCC · 55 |
| Lung Cancer | — | P1/2 | CCC · 48 |
| Burkitt Lymphoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. pd-1 knockout engineered t cells in Esophageal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pd-1-knockout-engineered-t-cells-esophageal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →